Abstract
The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer. Despite an incomplete evidence base, thiopurine immunomodulators remain a principle therapeutic option for patients failing aminosalicylate monotherapy and requiring multiple courses of corticosteroids. In this review, we outline the current evidence supporting the role of thiopurines in achieving these treatment goals in UC, including discussions of the important safety issues regarding their use. We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients.
Keywords: Azathioporine, 6-mercaptopurine, thiopurines, immunomodulators, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Colonoscopy, AZA, Nodular regenerative hyperplasia
Current Drug Targets
Title: Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
Volume: 12 Issue: 10
Author(s): Richard J. La Nauze and Miles P. Sparrow
Affiliation:
Keywords: Azathioporine, 6-mercaptopurine, thiopurines, immunomodulators, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Colonoscopy, AZA, Nodular regenerative hyperplasia
Abstract: The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer. Despite an incomplete evidence base, thiopurine immunomodulators remain a principle therapeutic option for patients failing aminosalicylate monotherapy and requiring multiple courses of corticosteroids. In this review, we outline the current evidence supporting the role of thiopurines in achieving these treatment goals in UC, including discussions of the important safety issues regarding their use. We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients.
Export Options
About this article
Cite this article as:
J. La Nauze Richard and P. Sparrow Miles, Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818180
DOI https://dx.doi.org/10.2174/138945011796818180 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review of Synthesis, Biological Assay and QSAR Studies of β-Secretase Inhibitors
Current Computer-Aided Drug Design The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety Studying the Gut Microbiome of Latin America and Hispanic/Latino Populations. Insight into Obesity and Diabetes: Systematic Review
Current Diabetes Reviews The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Colorectal Cancer – Increased Multidimensional Understanding of the Molecular Genesis
Current Cancer Therapy Reviews Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry Exploiting Significance of Physical Exercise in Prevention of Gastrointestinal Disorders
Current Pharmaceutical Design Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships - Part II)
Current Physical Chemistry The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Protein & Peptide Letters The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets